HealthyPhase 1NCT05491330
Bioequivalence Study of Nirmatrelvir & Ritonavir From Copaxid 150 +100 mg Tablets (Eva Pharma, Egypt) Versus Paxlovid 150 + 100 mg Film Coated Tablets (Pfizer Europe, Belgium)
A Phase 1 study testing Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference first dose), Nirmatrelvir 150 mg + Ritonavir 100 mg (test) and Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference second dose) in people with Healthy, run by Genuine Research Center, Egypt at 1 site in Egypt.
Trial summary
Comparative randomized, single dose, three-way, three-sequence, two treatment, partial replicate, crossover, open-label study to determine the bioequivalence of Nirmatrelvir \& Ritonavir From Copaxid 150 +100 mg Tablets (Eva Pharma, Egypt) Versus Paxlovid 150 + 100 mg Film Coated Tablets (Pfizer Europe, Belgium) Read more about this study
- Who is it for?
- Ages 18 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference first dose), Nirmatrelvir 150 mg + Ritonavir 100 mg (test) and Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference second dose)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 28 participants
- Where
- 1 siteEgypt
- Study dates
- 21 Aug 2022to 27 Oct 2022
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy male or female, age 18 to 55 years, inclusive.
- Body weight within 15% of normal range according to the accepted normal values for body mass index (BMI).
- Medical demographics without evidence of clinically significant deviation from normal medical condition, eg.: no history of heart, liver, kidney, gastrointestinal, nervous system, or metabolic abnormalities.
- Results of clinical laboratory test are within the normal range or with a deviation that is not considered clinically significant by principal investigator.
- Females should be on a suitable birth control method.
- Fully informed subjects that consented to participate in the study.
Who cannot join
- Subjects with known allergy to the products tested.
- Female subjects who were pregnant or nursing.
- Acute infection within one week preceding first study drug administration.
- History of drug or alcohol abuse.
- Subject does not comply with the stated instruction of not taking any prescription or non-prescription drugs within two weeks before first study drug administration and until the end of the study.
- Subject is on a special diet (for example subject is vegetarian).
Show all 12Show fewer
- Subject does not agree not to consume any beverages or foods containing methyl-xanthenes e.g. caffeine (coffee, tea, cola, chocolate etc.) 48 hours prior to the study administration of either study period until donating the last sample in each respective period.
- Subject does not agree not to consume any beverages or foods containing grapefruit 7 days prior to first study drug administration until the end of the study.
- Subject has a family history of severe diseases which have direct impact on the study.
- Participation in a bioequivalence study or in a clinical study within the last 8 weeks before first study drug administration.
- Subject intends to be hospitalized within 3 months after first study drug administration.
- Subjects who have donated blood or lost more than 500 mL blood within 3 months prior to the study.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Comparative Randomized, Single Dose, Three-way, Three-sequence, Two Treatment, Partial Replicate, Crossover, Open-label Study to Determine the Bioequivalence of Nirmatrelvir & Ritonavir From Copaxid 150 +100 mg Tablets (Eva Pharma, Egypt) Versus Paxlovid 150 + 100 mg Film Coated Tablets (Pfizer Europe, Belgium)
Comparative randomized, single dose, three-way, three-sequence, two treatment, partial replicate, crossover, open-label study to determine the bioequivalence of Nirmatrelvir \& Ritonavir From Copaxid 150 +100 mg Tablets (Eva Pharma, Egypt) Versus Paxlovid 150 + 100 mg Film Coated Tablets (Pfizer Europe, Belgium)
Read the detailed description
Primary Pharmacokinetic Parameters: Cmax, AUC0→t and AUC0→∞ Secondary Pharmacokinetic Parameters: Ke, tmax and t1/2e. ANOVA using 5% significance level for transformed (with the 90% confidence intervals) and untransformed data of Cmax, AUC0→t and AUC0→∞ and for untransformed data of Ke, tmax and t1/2e.
The confidence intervals of logarithmically transformed Test/Reference ratios for Cmax, AUC0→t and AUC0→∞ to be within 80.00-125.00%.
A comprehensive final report will be issued upon the completion of the study.
- Conditions
- Healthy
- Being tested
- Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference first dose), Nirmatrelvir 150 mg + Ritonavir 100 mg (test), Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference second dose)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference first dose)Drug
Also called Paxlovid
2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg
Nirmatrelvir 150 mg + Ritonavir 100 mg (test)Drug
Also called Copaxid
2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg
Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference second dose)Drug
Also called Paxlovid
2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg
| Study group | Role | What they receive |
|---|---|---|
| R reference (first dose) | Active comparator | Reference drug (Paxlovid) Nirmatrelvir 150 mg + Ritonavir 100 mg tablets Receives: Drug: Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference first dose) |
| T test | Experimental | Test drug (Copaxid) Nirmatrelvir 150 mg + Ritonavir 100 mg tablets Receives: Drug: Nirmatrelvir 150 mg + Ritonavir 100 mg (test) |
| R reference (second dose) | Active comparator | Reference drug (Paxlovid) Nirmatrelvir 150 mg + Ritonavir 100 mg tablets Receives: Drug: Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference second dose) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cmax
Maximal measured plasma concentration
Measured: Up to 48 hours post dose in each treatment period
Secondary outcomes (1)
Time of the maximum plasma concentration (Tmax)
The amount of time that a drug is present at the maximum concentration in serum
Measured: Up to 48 hours post dose in each treatment period
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Aug 2022
- Study start21 Aug 2022
- Primary completion4 Sep 2022
- Study completion27 Oct 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for HealthyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 28 participants (actual)
Sponsor and investigators
- Lead sponsor
- Genuine Research Center, Egypt
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Eva Pharma
- Responsible party
- Sponsor
- Investigators
- Ahmed Elshafeey, Ph.D. Pharma, Study director, Genuine Research Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05491330
- Sponsor's protocol ID
- GRC/1/22/1038
- Status last verified
- Jan 2023
- First submitted
- 4 Aug 2022
- Last updated
- 18 Jan 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Chow SC, Wang H. On sample size calculation in bioequivalence trials. J Pharmacokinet Pharmacodyn. 2001 Apr;28(2):155-69. doi: 10.1023/a:1011503032353.
PubMed 11381568Diletti E, Hauschke D, Steinijans VW. Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol. 1991 Jan;29(1):1-8.
PubMed 2004861Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987 Dec;15(6):657-80. doi: 10.1007/BF01068419.
PubMed 3450848
Study at a glance
From the registry record, last updated by the sponsor on 18 Jan 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparative Randomized, Single Dose, Three-way, Three-sequence, Two Treatment, Partial Replicate, Crossover, Open-label Study to Determine the Bioequivalence of Nirmatrelvir & Ritonavir From Copaxid 150 +100 mg Tablets (Eva Pharma, Egypt) Versus Paxlovid 150 + 100 mg Film Coated Tablets (Pfizer Europe, Belgium)
- ClinicalTrials.gov ID
- NCT05491330
- Acronym / sponsor ID
- GRC/1/22/1038
- Conditions
- Healthy
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 28 participants (actual)
- Lead sponsor
- Genuine Research Center, EgyptIndustry (pharma, biotech, devices)
- Collaborators
- Eva Pharma
- Study start
- 21 Aug 2022 (actual)
- Primary completion
- 4 Sep 2022 (actual)
- Study completion
- 27 Oct 2022 (actual)
- First posted
- 8 Aug 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Comparative randomized, single dose, three-way, three-sequence, two treatment, partial replicate, crossover, open-label study to determine the bioequivalence of Nirmatrelvir \& Ritonavir From Copaxid 150 +100 mg Tablets (Eva Pharma, Egypt) Versus Paxlovid 150 + 100 mg Film Coated Tablets (Pfizer Europe, Belgium)
Detailed description
Primary Pharmacokinetic Parameters: Cmax, AUC0→t and AUC0→∞ Secondary Pharmacokinetic Parameters: Ke, tmax and t1/2e. ANOVA using 5% significance level for transformed (with the 90% confidence intervals) and untransformed data of Cmax, AUC0→t and AUC0→∞ and for untransformed data of Ke, tmax and t1/2e.
The confidence intervals of logarithmically transformed Test/Reference ratios for Cmax, AUC0→t and AUC0→∞ to be within 80.00-125.00%.
A comprehensive final report will be issued upon the completion of the study.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| R reference (first dose) | Active comparator | Drug: Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference first dose)Reference drug (Paxlovid) Nirmatrelvir 150 mg + Ritonavir 100 mg tablets |
| T test | Experimental | Drug: Nirmatrelvir 150 mg + Ritonavir 100 mg (test)Test drug (Copaxid) Nirmatrelvir 150 mg + Ritonavir 100 mg tablets |
| R reference (second dose) | Active comparator | Drug: Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference second dose)Reference drug (Paxlovid) Nirmatrelvir 150 mg + Ritonavir 100 mg tablets |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Healthy male or female, age 18 to 55 years, inclusive.
- Body weight within 15% of normal range according to the accepted normal values for body mass index (BMI).
- Medical demographics without evidence of clinically significant deviation from normal medical condition, eg.: no history of heart, liver, kidney, gastrointestinal, nervous system, or metabolic abnormalities.
- Results of clinical laboratory test are within the normal range or with a deviation that is not considered clinically significant by principal investigator.
- Females should be on a suitable birth control method.
Key exclusion criteria (12 listed)
- Subjects with known allergy to the products tested.
- Female subjects who were pregnant or nursing.
- Acute infection within one week preceding first study drug administration.
- History of drug or alcohol abuse.
- Subject does not comply with the stated instruction of not taking any prescription or non-prescription drugs within two weeks before first study drug administration and until the end of the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference first dose)Also: Paxlovid2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg | Drug | R reference (first dose) |
| Nirmatrelvir 150 mg + Ritonavir 100 mg (test)Also: Copaxid2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg | Drug | T test |
| Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference second dose)Also: Paxlovid2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg | Drug | R reference (second dose) |
Primary outcome
Cmax
Time frame: Up to 48 hours post dose in each treatment period
Maximal measured plasma concentration
1 secondary outcome
Time of the maximum plasma concentration (Tmax)
Time frame: Up to 48 hours post dose in each treatment period
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jan 2023.
- Background: PubMed 11381568Chow SC, Wang H. On sample size calculation in bioequivalence trials. J Pharmacokinet Pharmacodyn. 2001 Apr;28(2):155-69. doi: 10.1023/a:1011503032353.
- Background: PubMed 2004861Diletti E, Hauschke D, Steinijans VW. Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol. 1991 Jan;29(1):1-8.
- Background: PubMed 3450848Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987 Dec;15(6):657-80. doi: 10.1007/BF01068419.
- Individual participant dataSharing planned: No
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ahmed Elshafeey, Ph.D. Pharma study director
Genuine Research Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference first dose), Nirmatrelvir 150 mg + Ritonavir 100 mg (test) and Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference second dose) in people with Healthy, run by Genuine Research Center, Egypt at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Jan 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cmax (time frame: Up to 48 hours post dose in each treatment period). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05491330, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jan 2023.